Patients with relapsed/refractory CLL who received zanubrutinib achieved significantly superior PFS compared with ibrutinib. The prescribing information for Brukinsa ® (zanubrutinib) has been updated ...
HONG KONG, Jan. 6, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced that the National Medical Products Administration has approved a significant label update in China for its internally developed, ...
Regulatory Challenges: Is a Surrogate End Point Instead of Overall Survival Enough for Regulatory Approval of (Neo)Adjuvant Cancer Treatment? The Swissmedic Perspective PFS depends on evaluation of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results